Holen Sie sich die Stockscreener-App
16.31
1.51%
-0.25
Schlusskurs vom Vortag:
$16.56
Offen:
$16.56
24-Stunden-Volumen:
558.93K
Relative Volume:
0.37
Marktkapitalisierung:
$1.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-7.2813
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
-6.32%
1M Leistung:
+15.18%
6M Leistung:
+231.50%
1J Leistung:
+109.37%
1-Tages-Spanne:
$16.24
$16.85
1-Wochen-Bereich:
$16.24
$18.15
52-Wochen-Spanne:
$3.5001
$18.15
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie GLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
16.31 | 1.08B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Franklin Resources Inc. Raises Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUE - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week HighStill a Buy? - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Nasdaq Futures Biotech Momentum - Kalkine Media
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - sharewise.com
Critical Survey: Monte Rosa Therapeutics (NASDAQ:GLUE) & Cogent Biosciences (NASDAQ:COGT) - Defense World
Monte Rosa Therapeutics stock hits 52-week high at $16.66 By Investing.com - Investing.com India
Monte Rosa Therapeutics stock hits 52-week high at $16.66 - Investing.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Monte Rosa Therapeutics (GLUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Improved Revenues Required Before Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock's 26% Jump Looks Justified - 富途牛牛
Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha
How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressuresQuarterly Earnings Summary & Real-Time Buy Signal Notifications - moha.gov.vn
Monte Rosa Therapeutics Jumps 124.9% in 2025 But Are Investors Getting Ahead of Themselves - Yahoo Finance
Hillsdale Investment Management Inc. Makes New $271,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
Monte Rosa Therapeutics, Inc. (GLUE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Head-To-Head Review: Twist Bioscience (NASDAQ:TWST) versus Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Inc. (GLUE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price momentum metrics for Monte Rosa Therapeutics Inc. explainedChart Signals & Proven Capital Preservation Tips - newser.com
Los Angeles Capital Management LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics finds novel molecular glue degrader - Traders Union
What to do if you’re stuck in Monte Rosa Therapeutics Inc.July 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
Integrated Quantitative Investments LLC Acquires New Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Reports Strong Revenue Growth - MSN
22,500 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Bailard Inc. - MarketBeat
What analysts say about Monte Rosa Therapeutics Inc stockFibonacci Retracement Levels & Free Explosive Earning Power - earlytimes.in
Is Monte Rosa Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Miss & Verified Trade Idea Suggestions - newser.com
Is it time to cut losses on Monte Rosa Therapeutics Inc.Quarterly Investment Review & Entry and Exit Point Strategies - newser.com
Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionMarket Volume Summary & Technical Pattern Alert System - newser.com
Custom watchlist performance reports with Monte Rosa Therapeutics Inc.Quarterly Growth Report & Community Driven Trade Alerts - newser.com
Why Monte Rosa Therapeutics Inc. stock is popular among millennialsJuly 2025 Highlights & Fast Moving Market Watchlists - newser.com
Published on: 2025-11-14 03:37:36 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO) - The Globe and Mail
Chart based exit strategy for Monte Rosa Therapeutics Inc.July 2025 Reactions & Safe Capital Growth Tips - newser.com
Trade Monte Rosa Therapeutics IncGLUE CFD - Capital.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap DownHere's Why - MarketBeat
GLUE Stock Price and Chart — NASDAQ:GLUE - TradingView
Forecasting Monte Rosa Therapeutics Inc. price range with options dataJuly 2025 Decliners & Long-Term Growth Plans - newser.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 10.8% Following Analyst Upgrade - MarketBeat
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):